Lactobacillus gasseri

Lactobacillus gasseri
Evidence Level
Limited
3 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

Lactobacillus gasseri is a lactic acid bacterium native to the human gastrointestinal tract, oral cavity, and breast milk. This page cites one human study: a randomized controlled trial in adults of a single strain, SBT2055, given in fermented milk, which reported modest reductions in abdominal fat (Kadooka 2013). Two things shape how much that is worth. First, with probiotics the strain is the product, so results for SBT2055 do not carry over to other L. gasseri strains such as BNR17, CECT5714 or LG21, and no study of those strains is cited here. Second, the product tested was a daily fermented milk drink, not a capsule, and a food can have effects of its own.

Studied Dose The one cited trial used strain SBT2055 delivered daily in fermented milk, not a capsule; there is no established consumer dose for L. gasseri.
Active Compound Live Lactobacillus gasseri bacteria. Only the SBT2055 strain has a supporting human trial cited on this page; BNR17, CECT5714 and LG21 are different strains with different research behind them.

Benefits

Abdominal fat: one trial, one strain, in fermented milk

This is the one benefit with a reference behind it. In a randomized, placebo-controlled trial in adults, a daily fermented milk drink containing L. gasseri SBT2055 reduced abdominal fat area by about 8% compared with the same drink without the bacteria, in 210 Japanese adults who started with above-average abdominal fat, over 12 weeks (Kadooka 2013). The effect faded within about 4 weeks of stopping, so any benefit lasts only as long as you keep taking it. Keep three limits in mind: the changes were modest, the product tested was a fermented milk drink rather than a capsule, and the research was run and funded by the dairy company that owns the strain. It is a single study, and it does not make L. gasseri a fat loss treatment.

BNR17: a different strain, with no study cited here

BNR17 is a different L. gasseri strain from the one in this page's cited trial, and no reference here supports it. With probiotics the strain is the product, so results for SBT2055 do not transfer to BNR17, and the weight and waist figures previously listed here came from a study that is not cited and was not verified. If a product advertises BNR17 weight loss numbers, ask which specific trial they come from.

H. pylori research on a different strain (not cited here)

LG21 (also called OLL2716) is another separate L. gasseri strain, studied mainly in Japan in people already infected with H. pylori. No study of it is cited on this page, so nothing here supports these claims, and results in infected patients would not describe what a probiotic does for a healthy person anyway. H. pylori infection is a medical condition that needs testing and treatment from a doctor, and a probiotic is not a treatment for it or for gastritis.

Mastitis and infant colic: a different strain, no study cited here

CECT5714 is yet another separate strain, and no reference on this page supports these claims. The comparison against simethicone comes from work that is not cited here and was not verified. Mastitis is an infection that needs medical care, and a baby who cries persistently should be assessed by a pediatrician rather than given a supplement. Never give a live probiotic to an infant without talking to their doctor first.

Mechanism of action

1

Bile salt hydrolase reducing dietary fat absorption

L. gasseri produces bile salt hydrolase enzymes that deconjugate bile acids in the small intestine. Deconjugated bile acids are less effective at emulsifying dietary fats, reducing fat absorption. This is a proposed explanation drawn mainly from laboratory work. It has not been shown to be the reason for the small changes seen in the one human trial cited on this page.

2

Adipocyte differentiation inhibition (PPAR-γ modulation)

L. gasseri metabolites (especially conjugated linoleic acid analogues produced by bacterial fermentation) inhibit adipocyte differentiation by suppressing PPAR-γ and CEBP-α transcription factors in cell culture models. This is cell culture work only. It has not been shown to happen in people, and no cited study here measured it.

3

Anti-inflammatory effects on adipose tissue

One idea being tested is that L. gasseri limits how much bacterial wall material (lipopolysaccharide) passes through the gut wall, which in theory would lower low grade inflammation. This comes from laboratory and animal research. The single human trial cited on this page did not establish changes in inflammatory markers such as TNF-alpha, IL-6 or CRP.

4

Gasseiricins — H. pylori-suppressing antimicrobials

Laboratory studies show that the OLL2716 and LG21 strains make bacteriocins (called gasseiricins) that can interfere with H. pylori in test systems. This is test tube evidence about strains other than the one in the cited trial, and no human study of it appears on this page.

Clinical trials

1
L. gasseri SBT2055 fermented milk and abdominal fat: the one cited trial
PubMed

Randomized, double-blind, placebo-controlled trial in adults comparing a daily fermented milk drink containing L. gasseri SBT2055 with the same drink without the bacteria. Main outcome: abdominal fat. (Kadooka et al. 2013, Br J Nutr, PMID 23614897. This is the only human study cited on this page.)

Adults with excess abdominal fat, drinking fermented milk containing the SBT2055 strain daily.

Abdominal fat fell modestly in the group drinking the L. gasseri SBT2055 fermented milk compared with the placebo milk. The limitations matter as much as the result: it is a single trial of a single strain, it was funded by the dairy company that owns the strain (Megmilk Snow Brand, formerly Snow Brand Milk Products), the product was a fermented milk drink rather than a capsule, and the changes were small. The 'L. gasseri for weight loss' positioning you see in marketing goes well beyond what this trial showed.

2
L. gasseri BNR17 for obesity: not supported by any reference on this page
PubMed

This card described a trial of BNR17, a different L. gasseri strain, that is not among the references cited on this page and was not verified. The details previously listed here have been removed for that reason.

Not applicable: no verified study of this strain is cited on this page.

No verified reference on this page supports these numbers, so they have been removed. BNR17 is a different strain from the SBT2055 used in the one cited trial, and results for one strain cannot be credited to the other. In general, probiotic effects on body composition reported in this area are small and do not replace changes in eating and activity.

3
L. gasseri CECT5714 for infant colic: not supported by any reference on this page
PubMed

This card described work on CECT5714, a different L. gasseri strain, in infants. It is not among the references cited on this page, was not verified, and the source was listed only as 'related infant colic probiotic trials'.

Infants. No verified study of this strain in infants is cited on this page, and infant use should always be discussed with a pediatrician first.

The crying time numbers previously listed here came from a source that is not cited on this page and was not verified, so they have been removed. What is worth keeping from this section: the probiotic with the better studied record in infant colic is a different species entirely, L. reuteri DSM 17938, and even there the benefit was seen in breastfed infants rather than formula fed ones. Colic in a baby is something for a pediatrician to assess, not something to self treat with a supplement.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated in healthy people. Live probiotics are not for everyone: anyone who is severely immunocompromised, critically ill, or has a central venous catheter should not take them without medical advice
Mild GI symptoms (gas, bloating) during initial supplementation week
Nothing in the single cited trial shows what happens after you stop taking it, so specific claims about benefits fading within a few weeks are not supported here

Important Drug interactions

Antibiotics — separate by 2+ hours
Bile acid binding drugs such as cholestyramine: this is a theoretical concern based on laboratory ideas about bile salts, not something any cited study measured
Generally no significant medication interactions

Frequently asked questions about Lactobacillus gasseri

What is Lactobacillus gasseri used for?

The one study cited on this page looked at abdominal fat, using the SBT2055 strain in a fermented milk drink, and found modest changes. Other uses you may see advertised, such as gut, stomach or vaginal health, are not supported by any reference on this page. Findings are strain specific, so keep expectations realistic and check which strain a product actually contains.

Does L. gasseri help with weight loss?

One trial cited here, using the SBT2055 strain in a daily fermented milk drink, found small reductions in abdominal fat. That is a single, company funded study of one strain in one delivery form. It is not a substitute for diet and exercise, and it is not a weight loss treatment.

How much L. gasseri should I take?

Products commonly provide a few billion CFU per day, but there is no established dose here. The one study cited on this page used the SBT2055 strain in a fermented milk drink rather than a capsule, so check that a label names the exact strain that was studied.

Is L. gasseri safe?

It is generally well tolerated. As with all live probiotics, severely immunocompromised or critically ill people should check with a doctor before use.

What is Lactobacillus gasseri?

Lactobacillus gasseri is a lactic acid bacterium native to the human gastrointestinal tract, oral cavity, and breast milk. This page cites one human study: a randomized controlled trial in adults of a single strain, SBT2055, given in fermented milk, which reported modest reductions in abdominal fat (Kadooka 2013).

What is the recommended dosage of Lactobacillus gasseri?

The clinically studied dose is The one cited trial used strain SBT2055 delivered daily in fermented milk, not a capsule; there is no established consumer dose for L. gasseri. Always follow the product label and check with a healthcare provider for personal advice.

Is Lactobacillus gasseri safe, and does it have side effects?

For most healthy adults, Lactobacillus gasseri is well tolerated at studied doses. Reported effects can include: Generally well tolerated in healthy people. Live probiotics are not for everyone: anyone who is severely immunocompromised, critically ill, or has a central venous catheter should not take them without medical advice Mild GI symptoms (gas, bloating) during initial supplementation… It may also interact with some medications. Lactobacillus gasseri is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Lactobacillus gasseri interact with any medications?

Possible interactions include: Antibiotics — separate by 2+ hours Bile acid binding drugs such as cholestyramine: this is a theoretical concern based on laboratory ideas about bile salts, not something any cited study measured If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Lactobacillus gasseri?

NutraSmarts rates the evidence for Lactobacillus gasseri as Limited (2 out of 5). It is backed by 3 clinical trials and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Kadooka Y, Sato M, Ogawa A, et al. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br J Nutr. 2013;110(9):1696-703..PubMedUsed to support: Randomized controlled trial of Lactobacillus gasseri SBT2055 given in fermented milk, reporting reduced abdominal fat in adults. This is the only human study cited on this page, and it covers the SBT2055 strain only.